West Pharmaceutical Services (WST) Asset Writedowns and Impairment (2011 - 2026)

West Pharmaceutical Services (WST) has reported Asset Writedowns and Impairment for 9 consecutive years, with $3.9 million the latest figure, recorded in Q2 2026.

• Quarterly Asset Writedowns and Impairment rose 2.63% year-over-year to $3.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $11.8 million (up 12.38% YoY) and the FY2025 annual result came in at $11.7 million, up 60.27% from the prior year.
• Asset Writedowns and Impairment advanced to $3.9 million in Q2 2026 per WST's latest filing, from $300000.0 in the prior quarter.
• Over the last five years, Asset Writedowns and Impairment for WST reached as high as $7.3 million in Q4 2025 and fell as low as $200000.0 in Q2 2022.
• A 5-year average of $2.3 million and a median of $1.5 million in 2023 frame the typical range for Asset Writedowns and Impairment.
• Annual changes were most pronounced in 2024 — Asset Writedowns and Impairment sank 80.0% — and 2025, when it surged 1166.67%.
• Year by year, Asset Writedowns and Impairment stood at $4.6 million in 2022, then slumped by 41.3% to $2.7 million in 2023, then surged by 100.0% to $5.4 million in 2024, then soared by 35.19% to $7.3 million in 2025, then slumped by 46.58% to $3.9 million in 2026.
• According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $3.9 million, $300000.0, and $7.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.